Drug firm Cadila Healthcare Ltd said its subsidiary received an approval from the US Food and Drug Administration (USFDA) to sell high blood pressure treatment tablets, Losartan Potassium and Losartan Potassium and Hydrochlorothiazide, in the that country.
The company will sell Losartan Potassium tablets in the strengths of 25mg, 50mg and 100mg, while it will sell Losartan Potassium and Hydrochlorothiazide tablets in the strengths of 50/12.5mg and 100/25mg, Cadila Healthcare said in a filing to the Bombay Stock Exchange.
The company has already launched both products in the US market. The drugs, which fall in the anti-hypertensive segment, have estimated market sales of $1.3 billion and $944 million, respectively in 2010, said Cadila Healthcare, quoting healthcare information solutions company NDC Health.
On Thursday, Cadila Healthcare shares ended 1.3% down at Rs684 on the Bombay Stock Exchange, while the benchmark Sensex declined 1.1% to 20,315 points.
Inside story of the National Stock Exchange’s amazing success, leading to hubris, regulatory capture and algo scam
Fiercely independent and pro-consumer information on personal finance.
1-year online access to the magazine articles published during the subscription period.
Access is given for all articles published during the week (starting Monday) your subscription starts. For example, if you subscribe on Wednesday, you will have access to articles uploaded from Monday of that week.
This means access to other articles (outside the subscription period) are not included.
Articles outside the subscription period can be bought separately for a small price per article.
Fiercely independent and pro-consumer information on personal finance.
30-day online access to the magazine articles published during the subscription period.
Access is given for all articles published during the week (starting Monday) your subscription starts. For example, if you subscribe on Wednesday, you will have access to articles uploaded from Monday of that week.
This means access to other articles (outside the subscription period) are not included.
Articles outside the subscription period can be bought separately for a small price per article.
Fiercely independent and pro-consumer information on personal finance.
Complete access to Moneylife archives since inception ( till the date of your subscription )
